The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence will likely see broad-based growth. Specialty products and biosimilars are expected to be key growth drivers. Hospitals are projected to continue outperforming with capacity additions and improving occupancy. Margins may contract due to higher costs and new facility ramp-up expenses.
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.